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A B S T R A C T
With the wider availability of antiretrovirals, the world’s HIV population is aging. More than 10% of the
34.5 million HIV-positive individuals worldwide are over the age of 50 years and the average age
continues to increase. In the USA more than 50% of the 1.3 million people with HIV are over 50 years old
and by the year 2030 it is estimated that 70% will be over the age of 50 years. Although the life expectancy
of HIV-positive people has increased dramatically, it still lags behind that of HIV-negative individuals.
There is controversy about whether HIV itself accelerates the aging process. Elevated rates of
inﬂammation seen in people with HIV, even if their viral loads are suppressed and their CD4 counts are
preserved, are associated with greater rates of cardiovascular, renal, neurocognitive, oncological, and
osteoporotic disease. These conditions increase exponentially in the elderly and will represent a major
challenge for HIV patients. In addition, conditions such as geriatric syndromes including frailty are also
seen at higher rates. Management of the aging HIV patient includes an emphasis on early diagnosis and
treatment, preventative measures for co-morbidities, and avoiding polypharmacy. Finally, the issue of
quality of life, prioritization of medical issues, and end of life care become increasingly important as the
patient grows older.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The epidemic caused by the human immunodeﬁciency virus
(HIV) was ﬁrst recognized in the USA in the early 1980s and shortly
afterwards throughout the world. It affected younger populations
with devastating effects. Before effective combination antiretrovi-
ral therapy (cART) became available in the 1990s, most patients
with HIV infection had an inexorable down-hill course dominated
by infections, tumors, wasting, and death. Now, in most instances,
patients with HIV treated with cART live with their disease
successfully.
As people living with HIV age, they face a variety of new
challenges including possible accelerated aging and higher rates of
co-morbidities such as cardiovascular disease. They also develop
geriatric syndromes and frailty earlier than uninfected people.
Thus patients with HIV on cART have far less life-threatening acute
illnesses, but must confront issues related to the aging process.* Corresponding author. Tel.: +1 401 793 4151.
E-mail address: Edward_Wing_MD@brown.edu
http://dx.doi.org/10.1016/j.ijid.2016.10.004
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The problem of aging in the HIV-positive population has been
recognized in high-income countries where the percentage of
people over the age of 50 years has increased rapidly, in many
cases to over 50%. Because much of the information on aging and
HIV has come from these countries, this review will concentrate
on reports from the USA and Western Europe. The same trends and
the same issues will become important in middle- and low-
income countries in the future. This review, therefore, will be
increasingly relevant to the care of HIV-positive patients
throughout the world.
This article is directed towards the general infectious diseases
community, as well as physicians and other practitioners directly
caring for patients with HIV. Issues covered include the epidemi-
ology of aging, the question of accelerated aging, co-morbidities,
geriatric syndromes and frailty, management, and the unique
psychosocial issues facing HIV patients.
2. History
HIV was ﬁrst recognized in the USA in 1981 as a fatal disease of
young gay men and intravenous (IV) drug users. The virus was
identiﬁed as the cause of HIV in 1983, and by 1985 there was aciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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tragically outlined in the The Band Played On by Randy Shilts,
published in 1987. By 1996 in the USA and Western Europe, there
was widespread use of effective combinations of antiretroviral
drugs initially termed highly active antiretroviral therapy or
HAART and now referred to as cART. The death rate from HIV began
to fall in 1996 in the USA, and the further availability of cART
worldwide saw a global decline in new cases for the ﬁrst time in
2012. This remarkable reversal of the prognosis of HIV caused a
dramatic shift in the demographics of people living with HIV.
3. Epidemiology of aging in people living with HIV
The age of people living with HIV has been rising steadily,
largely due to the success of cART. An estimated 3.6 million of the
35.6 million people worldwide living with HIV are over the age of
50 years and this trend is increasing steadily.1 In countries where
the epidemic was recognized earlier and effective therapy was
available in the mid-1990s, the age of people living with HIV has
increased dramatically. For example, in the USA approximately
40% of people living with HIV in 2012 were over the age of 50 years
and 11% were over the age of 60 years.1 By 2015 it was estimated
that 50% of people were over the age of 50 years. Less appreciated
are data indicating that 18% of newly diagnosed patients are over
the age of 50 years.2 Both of these factors, aging and new
acquisition later in life, have pushed up the average age of people
living with HIV.
A geographically speciﬁc example of this rise is demonstrated
by data from San Francisco, one of the epicenters of the epidemic in
the 1980s and 1990s. In 1990, the percentage of people living with
HIV in San Francisco who were over the age of 50 years was 10%. By
2010 it had reached 50%.3 Similar data have been reported from
New York City (New York City HIV/AIDS Annual Surveillance
Statistics 2013) and France.4
The same trends, although delayed, have also been documented
in low- and middle-income countries.1
4. Mortality and lifespan
There is great heterogeneity in the mortality ﬁgures and life
expectancy of people with HIV, driven by factors such as patient
virological suppression, CD4 nadir, time of diagnosis, and IV drug
use. Nonetheless, the overall mortality rate has fallen dramatical-
ly.5 Despite these advances, mortality rates in selected HIV-
infected populations range from 1.7- to 7.0-times those of HIV-
uninfected populations.6–10 Of great interest, subgroup analyses
indicate that mortality approaches the uninfected population if the
diagnosis of HIV is made early in the course of the disease, the CD4
count is maintained at >350–500 cells/ml, and the viral load is
suppressed.6
Similarly, calculated life expectancy, which is based on
mortality data, has risen since the late 1990s, but it is still only
two-thirds that of the general population.7,11–16 As with mortality
data, subgroup analyses indicate that those who achieve a CD4
count of above 350 cells/ml and viral suppression in the absence of
other risk factors have a life expectancy that is similar to the
general population.16
Caution regarding these studies, particularly the subgroup
analyses, is warranted. Patients in some cohort analyses are not
representative of the overall HIV-positive population, appropriate
HIV-uninfected controls are difﬁcult to identify, and data on aging
are still preliminary for the HIV epidemic. In particular, it is
difﬁcult to control for differences in lifestyle factors, socio-
economic status, risk factors for co-morbidities, nutrition, safe
environment, ethnicity, social isolation, and chronic infections
such as those caused by hepatitis and herpes viruses. The issues inidentifying appropriate non-HIV-infected control populations has
been reviewed recently.17
A recent article compared life expectancy of HIV-positive and
matched HIV-negative individuals (rather than the general
population) cared for in the Kaiser Permanente Health System
in California from 1996 (at the beginning of widespread cART in the
USA) to 2011.18 The life expectancy at age 20 years of an HIV-
positive individual rose from 19.1 years to 53.1 years by 2011, but
was still less than that of HIV-negative individuals (64.9 years).
After controlling for risk factors including cART therapy, smoking,
substance abuse, and hepatitis virus infection, a gap between HIV-
positive and HIV-negative individuals of almost 6 years of life
expectancy was still demonstrated. Thus the best data, i.e. HIV-
positive individuals compared to matched HIV-negative individu-
als rather than the general population, indicate a continuing gap in
life expectancy for HIV-positive individuals compared to those
who are uninfected.
5. Changing causes of death
Data on cause of death from six different cohorts in developed
countries after 1996 have demonstrated a dramatic fall in the rate
of AIDS-related infections and malignancies. The rate of non-AIDS-
related causes of death has fallen as well, but not as dramatical-
ly.5,19–23 These studies show widely varying causes of death
depending on the characteristics of each cohort, but some
important trends are clear. In the cART era, HIV-related causes
of death remain important, but occur primarily in patients with
delayed or ineffective treatment (non-adherence, drug resistance,
poor CD4 recovery). The rates of liver disease, cardiovascular
disease, and non-HIV-related infection have either fallen slightly or
remained the same in the cART era. In contrast, the rate of death
caused by non-HIV-related malignancies has increased.19,23 Other
causes of death in the cART era include non-AIDS-related
infections, renal disease, substance abuse, violence, and suicide.6,20
6. Does HIV accelerate aging?
The data quoted above suggest that HIV itself may accelerate
the aging process. Aging has been broadly deﬁned as ‘‘the time-
dependent functional decline that affects most living organ-
isms.’’24 Multiple biological mechanisms for aging have been
described, some of which may affect HIV-positive individuals at
higher rates.24,25 These mechanisms are discussed in detail by
Lopez-Otin et al.24 and include genetic instability, telomere
shortening, epigenetic alterations, loss of proteostasis, deregulated
nutrient-sensing, mitochondrial dysfunction, cellular senescence,
stem cell exhaustion, and altered intercellular communication. The
latter includes abnormal endocrine and neuroendocrine signaling,
as well as immune dysregulation. Immune dysregulation, immune
cell senescence, and chronic inﬂammation found even in HIV-
positive patients virally suppressed on cART appear to be most
important. For example HIV-positive individuals have increased
serum levels of interleukin (IL)-6, a marker of inﬂammation that is
associated with chronic illnesses including cancer and cardiovas-
cular disease, with overall ﬁtness, as well as with increased
mortality.26–29 Other biomarkers have also been shown to be
increased in HIV-positive patients, including D-dimer, a pro-
thrombotic protein.30,31 There are probably multiple mechanisms
accounting for increased inﬂammation in HIV-positive individuals,
as outlined below.
1. Low-level tissue viral infection with HIV, even in patients
treated with effective cART who have undetectable serum virus.
While controversial, recent evidence based on both tissue and
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viral replication.32–34 Both studies used genetic analysis to
estimate viral evolution and mutation over time . In spite of
cART, viral evolution continued for 6 months in one study and
for 6 years in the other, suggesting ongoing tissue replication
despite cART. It is important to note that viral evolution is not a
direct measure of tissue viral replication. Analysis of the data
from these studies required sophisticated statistical methods to
infer tissue viral replication. Thus, further studies including
more direct methods will be required to conﬁrm these ﬁndings.
2. Chronic viral reactivation of herpes viruses, particularly
cytomegalovirus, in HIV.35
3. Microbial translocation, i.e. penetration of gut microbes and
their products into the systemic circulation due to abnormal gut
immunity despite effective cART.36
4. Immune dysregulation and senescence with depletion of CD4+ T
cells, increased numbers of senescent CD8 T cells
(CD57 + CD28  ) that secrete cytokines, and increased mono-
cyte activation.37 Immune senescence occurs at a younger age in
HIV-infected patients than in elderly non-HIV-infected persons.
Functionally, this results in a decreased ability to respond
immunologically to new antigens, pathogens, and vaccines, as
well as an increased inﬂammatory state.
Interestingly, each of these mechanisms has also been
described in elderly HIV-negative individuals as part of the normal
aging process.38
Other biological mechanisms of aging have also been described
in HIV-positive persons at higher rates, including mitochondrial
dysfunction, dysfunction of the growth hormone/insulin-like
growth factor/insulin pathway that regulates cell growth and
metabolism, telomere shortening, and epigenetic changes.24
Whether these inﬂammatory and immune changes translate
into accelerated aging is controversial.38,39 It is important to
emphasize that changes in inﬂammation, immune dysfunction,
physical functional changes, e.g. geriatric syndromes and frailty
(see below), and co-morbidities have not always been correlated.
While each of these has been identiﬁed in HIV-positive popula-
tions, it is not clear that they cause accelerated aging.
Arguments supporting accelerated aging processes in HIV
patients include the presence at younger ages of the following
changes: (1) increased rates of chronic co-morbidities, (2)
increased rates of geriatric syndromes and frailty, (3) senescent
immune changes, and (4) persistent increased inﬂammatory
markers termed inﬂamm-aging.40 Consistent with these ﬁndings
are the increased mortality and reduced lifespan of HIV-positive
populations compared to the general population.
However, arguments against accelerated aging in HIV-positive
patients include the fact that the life expectancy of HIV-positive
patients with CD4 counts >500 cells/ml and suppressed viral loads
on cART in some cohorts is no different to that of the general
population.7,15,16 In addition while co-morbidities occur at higher
rates in the HIV population for any given age, the rate of co-
morbidities does not increase with the length of time a person is
infected with HIV. HIV may be a risk factor for co-morbidities, but
does not appear to accelerate their occurrence over time.41,42
Further mechanistic and epidemiological data will be needed to
clarify this ongoing controversy.
7. Increased risk of chronic non-AIDS diseases in HIV-positive
patients
Patients with HIV have an increased number of co-morbidities
compared to those without HIV.43 These co-morbidities occur at
high rates at all ages in HIV-positive patients, but will become
increasingly important as this population ages. The followingsections review data indicating increased risk in HIV-positive
people for certain co-morbidities.
7.1. Cardiovascular disease and stroke
In the pre-cART era, HIV-positive patients were at risk of
myocarditis and dilated cardiomyopathy, usually associated with a
low CD4 count.44 With the advent of effective cART, these
conditions have faded, and HIV-positive patients are recognized
to be at increased risk of chronic cardiovascular disease including
coronary artery disease, myocardial ﬁbrosis, congestive heart
failure, and ischemic stroke.45–47 For example, data from the
Veteran Aging Cohort Study in HIV-positive individuals showed a
1.5-times increased risk of acute myocardial infection and a 1.17-
times increased risk of stroke at all ages, even in those with
suppressed viral loads.48,49 Similar increased risks have been noted
in other cohort studies, although the risk seems to have decreased
in recent years, perhaps due to improved risk reduction through
the use of statins.50,51 Certain antiretroviral drugs may increase
cardiovascular risk, including protease inhibitors, which induce a
poor metabolic proﬁle including hyperlipidemia compared to
other drugs such as integrase inhibitors. The association of
abacavir with cardiovascular disease noted in early studies has
not been conﬁrmed in all studies and remains controversial.47
Other cardiovascular risk factors seen commonly in HIV-positive
populations include smoking, hypertension, insulin resistance,
increased inﬂammatory and thrombotic markers, and more
recently obesity.
7.2. Osteoporosis and fracture
Osteopenia and osteoporosis in HIV patients are increased
compared to the general population; the cause is likely multifac-
torial. Risk factors such as substance abuse (particularly alcohol),
smoking, low body weight, and vitamin D deﬁciency contribute to
the increased risk in HIV-positive patients.52 In addition, the direct
effects of cART, particularly those due to protease inhibitor-based
and tenofovir-based regimens, predispose to loss of bone densi-
ty.53 Chronic HIV infection itself is also a contributor, as HIV
infection appears to confer an increased risk of osteoporosis in
cross-sectional cohort-based studies. The risk of fracture in HIV-
infected individuals has been found to be increased almost three-
fold.42,54
7.3. Metabolic syndrome and diabetes mellitus
The metabolic syndrome has been characterized by central
obesity, hypertension, and metabolic abnormalities such as high
fasting blood glucose and low high density lipoprotein levels,
which confer a signiﬁcant risk for cardiovascular disease and
diabetes.55,56 The risk of metabolic syndrome in HIV patients,
relative to non-HIV patients, has been found to be increased in
some studies and decreased in others.56,57 Similarly, the risk of
developing diabetes mellitus in HIV populations is not well
established.58 Studies earlier in the epidemic, when early cART
regimens predominated, demonstrated an increased risk of
diabetes mellitus in HIV-positive patients, whereas later studies
have not consistently shown this relationship.59
7.4. Renal disease
Early in the HIV epidemic, a unique form of progressive renal
disease was recognized primarily in African Americans, termed
HIV nephropathy.60 With the introduction of effective cART in the
1990s, the incidence of HIV nephropathy decreased markedly.
However, the current prevalence of chronic renal disease remains
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uninfected individuals.42,61 The prevalence of chronic kidney
disease stage 3 (glomerular ﬁltration rate of 30–59 ml/min) has
ranged from 3.5% to 9.7%.61 Risk factors for renal disease in HIV-
positive individuals include age, black race, diabetes mellitus,
hypertension, low CD4 counts, high viral loads, inﬂammatory
markers, and certain cART drugs such as tenofovir.62
7.5. Chronic neurological complications
In the pre-cART era, neurological disease in AIDS patients was
dominated by infectious complications of AIDS (CD4 <200 cells/
ml), as well as HIV-associated dementia, myelopathy, and
peripheral neuropathy.63
Despite a dramatic decrease in these conditions in the era of
cART, HIV infection continues to be associated with neurocognitive
disease termed HIV-associated neurocognitive disorders or
HAND.64 Approximately 50% of all HIV-positive individuals have
some degree of neuropsychological impairment. Most are asymp-
tomatic, but up to 12% may have mild and 2% severe disorders.42,64
The risk of dementia in one cohort was increased for older HIV-
infected patients (>50 years old) compared to younger HIV-infected
patients (20–39 years old) by more than three-fold.65 Changes seem
to correspond to changes in brain volume.66 Risk factors for HAND
include age, history of immune suppression, other co-morbidities
and disease indicators, psychiatric disorders, IQ, previous brain
trauma, and infection, as well as co-infection with hepatitis C virus
(HCV).67,68 Unlike Alzheimer’s disease, HAND is not necessarily
progressive.67,69 Treatment with both pharmacological and non-
pharmacological approaches is an area of active research.70,71 As the
HIV-positive population ages, the intersection of HAND with age-
related neurological conditions including dementia and Alzheimer’s
disease will be of great importance.
7.6. Malignancies
Increased rates of Kaposi’s sarcoma and non-Hodgkin B cell
lymphoma were recognized early in the HIV epidemic. Kaposi’s
sarcoma had rates of 1000 times and non-Hodgkin B cell
lymphoma had rates 100 times those in non-HIV populations.72
Subsequently other malignancies were noted to occur more
frequently in HIV patients, including primary central nervous
system lymphoma, invasive squamous cell carcinoma of the cervix,
lung cancer, anal cancer, Hodgkin lymphoma, liver cancer, and
head and neck squamous cell cancer. With the advent of effective
cART in the mid-1990s, a dramatic fall in the incidence of many
malignancies, particularly Kaposi’s sarcoma and non-Hodgkin B
cell lymphoma, was noted.73–75 The incidence of other virally
related cancers, however, has either remained the same or has
increased somewhat.42 Rates of skin and lung cancer remain high,
but the rates of breast, colon, and prostate cancers are not
increased when compared to the general population.76,77
As the HIV-positive population ages, the rates of all cancers,
particularly lung, prostate, colorectal, and breast, will increase.78
The estimated cumulative incidence of cancer by the age of
75 years for HIV-positive patients is increased for Kaposi’s
sarcoma, non-Hodgkin B cell lymphoma, lung cancer, anal cancer,
liver cancer, and Hodgkin lymphoma, in HIV-positive
individuals.76 Furthermore, cancer-related mortality rates for
HIV-positive patients remain high for many cancers.79
7.7. Quality of life in older patients with HIV
Older patients with HIV face a number of factors that affect their
quality of life, including increasing physical disabilities and
morbidities, psychiatric illnesses, losses of partners and friends,social isolation, and stigma. Added to this are additional stressors
often experienced by older HIV patients, including unemployment,
poverty, and crime. In a poignant qualitative study, the changes
experienced by aging HIV-positive patients were categorized as
physical challenges, internal changes, stigma, and in particular, a
sense of lost community and social support described by one
participant as ‘‘a shrinking kind of life’’.80
In a case-controlled study from San Diego, older HIV-positive
patients were found to have worse physical and mental function-
ing and greater psychosocial stress than HIV-negative patients.81
Interestingly, however, there were no differences in measures of
optimism, personal mastery, and social support. In a separate
study, HIV patients with strong resilience measures seemed to
manage the stress of aging, including physical and emotional
challenges, better than those who had weak resilience measures.82
Interventions focusing on improving factors such as social support
and resilience may improve the quality of life of HIV-positive
patients who are aging.
7.8. Geriatric syndromes and frailty
The term ‘geriatric syndromes’ has been used to describe a wide
variety of conditions associated with aging that predict adverse
clinical outcomes.83 For HIV patients, geriatric syndromes gener-
ally include the following: falls, urinary incontinence, difﬁculty
with activities of daily living, slow gait, sensory deﬁcits such as
hearing and sight loss, and neurocognitive impairment.84
Studies have demonstrated a high incidence of geriatric
syndromes in HIV-positive individuals over the age of 50 years.84
In one study, more than half (53%) of the individuals had two or
more geriatric syndromes, with the most frequent conditions being
prefrailty (modiﬁed Fried criteria–see below), difﬁculty with
activities of daily living (ADLs), and neurocognitive impairment.
Geriatric syndromes include frailty, which by itself confers a risk
of morbidity, hospitalization, and mortality. The Fried criteria,
which represent the most commonly accepted deﬁnition of frailty,
are based on the assessment of weight loss, strength, endurance,
walking speed, and activity level.85 Multiple studies have demon-
strated that patients with HIV are more susceptible to developing
frailty at earlier ages than the general population,86,87 and thus are
more susceptible to adverse outcomes.88 Risk factors for frailty
include low current CD4 and low nadir CD4 counts, other co-
morbidities such as hepatitis C, central obesity, and other geriatric
syndromes, as well as social factors including lower education.86
As the HIV-positive population ages, the rates of frailty will
increase and will represent an important challenge for clinicians.
Although few data exist on the prevention or treatment of frailty,
potential strategies include early diagnosis and treatment of HIV,
identifying and treating co-morbidities, and exercise.86,89
8. Care of the patient
Recommended guidelines for the treatment of older patients
with HIV can be found in the executive summary of the HIV and
Aging Consensus Project, a joint project between the American
Academy of HIV Medicine, the American Geriatrics Society, and the
AIDS Community Research Initiative of America,90 and in the
guidelines for the treatment of HIV-positive individuals available
from the Department of Health and Human Services (DHHS)
(http://aidsinfo.nih.gov). An overall approach to the care of the
older patient with HIV can be found in the article by Greene et al.91
Also important for the care of the elderly patient are the Primary
Care Guidelines for the Management of Persons Infected with HIV:
2013 Update by the HIV Medicine Association of the Infectious
Diseases Society of America (IDSA).92 The following are brief
comments regarding the above guidelines for diagnosis and
Table 1
Suggested management guidelines for newly diagnosed HIV patients over 50 years of agea
Recommendations Comments
1. Comprehensive history, including sexual history and physical
examination
Include screening for hypertension, obesity, depression (e.g., Geriatric
Depression Scale), smoking and substance abuse
2. Complete blood and chemistry panel
3. Plasma HIV RNA (viral load) Once stable on cART every 6 months
4. Blood CD4 count and percentage Once stable on cART every 6–12 months
5. HIV resistance testing Initially and for elevated viral load
6. Treatment with cART for all patients by August 1, 2016 guidelines Follow DHHS guidelines http://aidsinfo.nih.gov/guidlines
7. Screening for syphilis, chlamydia, gonorrhea Repeat periodically if indicated
8. Fasting lipids and cardiovascular risk Lipids initially and 3 months after starting cART; base treatment on ACC/
AHA guidelines (http://www.nhlb.nih.gov)
9. Urinalysis, creatinine clearance, and urine protein Annually
10. Hepatitis A, B, C screening Vaccination (A, B) and treatment (C)
11. Tuberculosis screening Repeat if indicated
12. Vaccination for inﬂuenza Annually
13. Vaccination for pneumococcal infection
14. Cervical Pap and HPV screen Initially; if negative every 3 years; http://aidsinfo.nih.gov/guidelines
15 Baseline DEXA screen for men and women >50 years of age
16. Fasting blood glucose and HbA1c for diabetes Initially, 1–3 months following initiation of cART, and then annually
17. Mammography for women >50 years Annually
18. Colonoscopy Age 50–75 years
19. Low resolution lung CT cancer screening >30 pack/year smoking history who smoke or quit in the last 15 years;
age >55–80 years; annually
20. Ultrasound for abdominal aortic aneurysm Men age 65–75 years who have ever smoked
21. Chest X-ray If positive TB test or presence of other pre-existing lung condition
cART, combination antiretroviral therapy; DHHS, Department of Health and Human Services; ACC/AHA, American College of Cardiology/American Heart Association; HPV,
human papillomavirus; DEXA, dual-energy X-ray absorptiometry; HbA1c, glycated hemoglobin; CT, computed tomography; TB, tuberculosis.
a Guidelines are based on Aberg et al.92 and the Department of Health and Human Services guidelines (http://aidsinfo.nih.gov/guidelines for the care of patients with HIV).
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prioritization of elderly HIV-positive patients. Table 1 summarizes
suggested management guidelines for newly diagnosed HIV
patients over 50 years of age.
8.1. Diagnosis and treatment of HIV
The diagnosis of HIV remains a problem in older patients, as
screening and diagnosis of older patients for HIV has not been
emphasized and is frequently overlooked by both physicians and
patients. Data indicate that 18% of newly diagnosed patients are
over the age of 50 years.2 Screening for HIV should be considered
for all older adults.90
Treatment with cART should be offered to all HIV-positive
patients unless there is a medical or pharmacological contraindi-
cation. A recent study indicated that patients in the age range 45–
60 years have a higher mortality than younger patients if
antiretroviral treatment is delayed.93 Key considerations include
the following:
1. All patients over age 50 years should be offered cART treatment
for HIV. Guidelines are available at http://aidsinfo.nih.gov/
guidelines.
2. The choice of cART will be inﬂuenced by underlying co-
morbidities (e.g., renal disease).
3. Resistance testing should be performed at the time of initiation
of cART.
4. cART side effects including bone, kidney, metabolic, cardiovas-
cular, and liver are more common in the elderly, and side effects
should be monitored carefully. Newer drug options, such as
tenofovir alafenamide in place of tenofovir disoproxil fumarate,
may reduce side effects such as bone and renal toxicity.94
5. Routine monitoring of CD4 count and HIV RNA levels should be
done according to guidelines. CD4 responses to cART are
reduced in older patients compared to younger patients, and this
poor response may be related to greater clinical progression.95,96
There are no differences in virological responses between older
and younger patients.6. Because of polypharmacy, older patients are more prone to
drug–drug interactions. Drug–drug interactions have been
reviewed recently.97
7. Although adherence by older adults may be better than younger
ones,98 a recent study using Medicaid data on over 5000 patients
indicated that only 32% of participants had optimal adherence.99
An increased number of co-morbidities and living in rural areas
and small metropolitan areas were risk factors for lower
adherence.
8.2. Behavioral risk factors for HIV
Many people with HIV have higher rates of smoking,100
substance abuse including alcohol,101 and low ﬁtness and physical
activity levels.102 Each of these behaviors should be assessed at the
initiation of care, and strategies to address these issues should be
discussed with the patient. Smoking in particular has been shown
to increase the risk of cardiovascular disease, chronic lung disease,
and malignancy in HIV-positive individuals. With the rise in
obesity, HIV individuals will be at risk of diabetes mellitus and
hypertension. Nutritional advice and weight reduction programs
should be offered.
A sexual history should be taken at each visit. As with other
HIV-positive populations, and consistent with primary care
guidelines, patients should be screened for high-risk sexual
behavior and evidence of sexually transmitted infections at each
visit. Prevention including behavioral and pharmacological
approaches (pre-exposure prophylaxis or PrEP) should also be
emphasized with this population if appropriate.
8.3. Screening and prevention for co-morbidities
Standard guidelines for HIV-negative individuals should be
followed for the screening, risk assessment, and treatment of both
cardiovascular disease and dyslipidemia for HIV-positive patients
(for example the American College of Cardiology/American Heart
Association risk calculator). Screening hyperlipidemia should be
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interactions of hydroxymethylglutaryl coenzyme A (HMG co-A)
reductase inhibitors with cART are a concern in HIV-positive
individuals with indications for statins.97 These can be minimized
by using pravastatin, pitavastatin, and to some extent, low-dose
atorvastatin and rosuvastatin.
Older patients with HIV are particularly prone to renal disease
secondary to drugs (e.g., tenofovir), HIV itself (HIV nephropathy
(HIVN)), hypertension, or diabetes. All HIV-positive patients
should have annual measurements of serum creatinine and
urinary protein excretion.
All HIV patients should be screened for hepatitis A, B, and C
initially, and appropriate vaccinations should be given if the
patients are not immune to hepatitis A virus or hepatitis B virus.
Identiﬁcation of hepatitis C has become particularly important,
because patients co-infected with HIV and HCV have an increased
risk of developing progressive cirrhosis as well as hepatocellular
carcinoma. Because of the truly remarkable advances using oral
treatment for hepatitis C, most patients co-infected with HIV and
HCV should be considered for treatment.103 Individuals co-infected
with HIV and HCV have been listed as ‘high priority’ for treatment
in the latest American Association for the Study of Liver Disease
(AASLD) guidelines.
Other immunizations, including yearly inﬂuenza vaccination
and appropriate vaccination for pneumococcal disease, are
important preventative measures.
Cancer screening by current guidelines is important because of
the increased risk of cancer as patients age (see above). DHHS
guidelines recommend that HIV-infected women should have a
cervical Pap test and human papillomavirus (HPV) testing initially,
and if negative repeated every 3 years (DHHS guidelines at http://
aidsinfo.nih.gov/guideliness). Although controversial, many prac-
titioners recommend that HIV-infected men, HIV-infected women
practicing receptive anal intercourse, and those with anal warts
should have an annual anal Pap test.
Screening for osteoporosis by bone density scanning and
assessment of the risk of fracture should be performed (e.g., FRAX
calculator) in older patients, and treatment should be offered when
appropriate.104 IDSA guidelines recommend screening for osteo-
porosis at age 50 years for HIV-positive individuals, rather than age
65 years as recommended for the general population. Preventative
therapy with vitamin D (HIV patients are often vitamin D deﬁcient)
and calcium should be routine in older HIV-positive patients.105
Dysregulation of endocrine pathways may occur in HIV
individuals. Screening for diabetes mellitus consisting of a fasting
blood glucose and glycated hemoglobin (HbA1c) should be
obtained prior to and within 1–2 months after starting cART.
Similarly, screening for hyperlipidemia should be performed
before and 1–3 months after starting cART. Hypogonadism
hallmarked by decreased libido and erectile dysfunction is
common in elderly HIV-positive men, and, if indicated, should
be screened for with a morning serum testosterone level. Androgen
replacement therapy may be indicated if testosterone levels are
low. Although controversial, hormone replacement therapy for
menopausal women in those with severe menopausal symptoms
can be considered.92
Older patients should be screened for depression (with tools
such as the Geriatric Depression Scale), and, if present, treatment
with selective serotonin reuptake inhibitors (SSRIs) or cognitive
and behavior therapy should be considered as ﬁrst-line therapy.106
Non-benzodiazepine agents are preferred for the long-term
treatment of anxiety, particularly because of concern for drug–
drug interactions with benzodiazepine agents (especially diaze-
pam, alprazolam, and midazolam). In addition, patients should be
screened for neurocognitive impairment and referred for treat-
ment if appropriate. A widely used although imperfect tool todetermine neurocognitive impairment is the Montreal Cognitive
Assessment.107
Polypharmacy is a major risk for HIV-positive patients because
cART consists of at least three drugs and the treatment of co-
morbidities often brings the total to 10 or more drugs. Data from
non-HIV geriatric populations indicate that taking ﬁve or more
drugs increases the risk of adverse drug events, drug interactions,
inappropriate medication use, delirium, falls, fractures, and poor
adherence. Medication interactions between cART and other
medications are a major consideration, particularly the cyto-
chrome p450 inhibition that occurs with protease inhibitors (e.g.,
darunavir) and non-nucleoside reverse transcription inhibitors
(e.g., efavirenz). Regular review of all medications prescribed to a
patient with regard to drug interactions, toxicity, and necessity is
important.
8.4. Prioritization
Perhaps most important is to recognize that HIV-positive
patients develop an increasing number of co-morbidities as they
age. Stages of aging, priority driven care for co-morbidities, and
issues of social isolation in the aging are discussed in more detail in
the article by Greene et al.91 The expectations of aging patients and
the appropriate therapy for these patients will be different than
those of younger patients and will evolve over time. For example,
aggressive therapy of an advanced medical condition may be
inappropriate for an older patient whose quality of life may be far
more important than the potential beneﬁt of treatment with risks
and side effects. Communication between care givers and the
patient becomes essential in establishing agreed-upon goals of
treatment. Finally, advance directives are frequently overlooked in
the care of HIV-positive patients, but take on increased importance
for the elderly patients.
The prognosis of people living with HIV has improved
dramatically over the past 20 years, but increased rates of co-
morbidities as well as frailty and neurocognitive changes as they
age pose challenges to patients and their caregivers. Early
diagnosis, appropriate treatment and prevention, as well as
appropriate geriatric care, will be essential to the wellbeing of
this important patient population.
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